Jatinder K Lamba
Overview
Explore the profile of Jatinder K Lamba including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1827
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Thomas M, Li J, King K, Persaud A, Duah E, VanGundy Z, et al.
Haematologica
. 2023 Mar;
108(8):2155-2166.
PMID: 36861411
Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been associated with DNA repair efficiency. Here we...
12.
Marrero R, Cao X, Wu H, H Elsayed A, Klco J, Ribeiro R, et al.
Blood Adv
. 2023 Jan;
7(11):2538-2550.
PMID: 36689724
Cytarabine arabinoside (Ara-C) has been the cornerstone of acute myeloid leukemia (AML) chemotherapy for decades. After cellular uptake, it is phosphorylated into its active triphosphate form (Ara-CTP), which primarily exerts...
13.
Lim J, Madabushi S, Vishwasrao P, Song J, Abdelhamid A, Ghimire H, et al.
Front Oncol
. 2022 Nov;
12:1045016.
PMID: 36439420
Total body irradiation (TBI) is a commonly used conditioning regimen for hematopoietic stem cell transplant (HCT), but dose heterogeneity and long-term organ toxicity pose significant challenges. Total marrow irradiation (TMI),...
14.
Brooks J, P Solans B, Lu Y, Kharbanda S, Dvorak C, Lalefar N, et al.
Pharmaceutics
. 2022 Nov;
14(11).
PMID: 36432661
Fludarabine is a nucleoside analog with antileukemic and immunosuppressive activity commonly used in allogeneic hematopoietic cell transplantation (HCT). Several fludarabine population pharmacokinetic (popPK) and pharmacodynamic models have been published enabling...
15.
Nguyen N, Rafiee R, Tagmount A, Sobh A, Loguinov A, de Jesus Sosa A, et al.
Blood Adv
. 2022 Sep;
7(9):1769-1783.
PMID: 36111891
Etoposide is used to treat a wide range of malignant cancers, including acute myeloid leukemia (AML) in children. Despite the use of intensive chemotherapeutic regimens containing etoposide, a significant proportion...
16.
Gbadamosi M, Shastri V, H Elsayed A, Ries R, Olabige O, Nguyen N, et al.
Leukemia
. 2022 Jun;
36(8):2022-2031.
PMID: 35688939
Gemtuzumab ozogamicin (GO) is an anti-CD33 monoclonal antibody linked to calicheamicin, a DNA damaging agent, and is a well-established therapeutic for treating acute myeloid leukemia (AML). In this study, we...
17.
Lamba J, Pounds S
Haematologica
. 2022 Jan;
107(10):2288-2289.
PMID: 35021610
No abstract available.
18.
H Elsayed A, Cao X, Mitra A, Wu H, Raimondi S, Cogle C, et al.
J Clin Oncol
. 2022 Jan;
40(7):772-783.
PMID: 34990262
Purpose: To establish a patient-specific polygenic score derived from cytarabine (ara-C) pathway pharmacogenomic evaluation to personalize acute myeloid leukemia (AML) treatment. Materials And Methods: Single nucleotide polymorphisms (SNPs) in the...
19.
Fornerod M, Ma J, Noort S, Liu Y, Walsh M, Shi L, et al.
Blood Cancer Discov
. 2021 Nov;
2(6):586-599.
PMID: 34778799
Significance: Immunophenotype and somatic mutations play a significant role in treatment approach and risk stratification of acute leukemia. We conducted an integrated genomic analysis of pediatric myeloid malignancies and found...
20.
Yang G, Singh S, McDonough C, Lamba J, Hamadeh I, Holliday L, et al.
Clin Pharmacol Ther
. 2021 Aug;
110(6):1558-1569.
PMID: 34390503
Medication-related osteonecrosis of the jaw (MRONJ) is a rare but serious drug-related adverse event. To identify pharmacogenomic markers of MRONJ associated with bisphosphonate therapy, we conducted a genomewide association study...